• Explore /
  • Poster
  • / Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive <I>EGFR</I> mutations: NEJ005/TCOG0902.

Randomized phase II study of concurrent gefitinib and chemotherapy versus sequential alternating gefitinib and chemotherapy in previously untreated non-small cell lung cancer (NSCLC) with sensitive EGFR mutations: NEJ005/TCOG0902.

Abstract Poster

Authors

null

Satoshi Oizumi

First Department of Medicine, Hokkaido University School of Medicine, Sapporo, Japan

Satoshi Oizumi , Shunichi Sugawara , Koichi Minato , Toshiyuki Harada , Akira Inoue , Yuka Fujita , Makoto Maemondo , Hirohisa Yoshizawa , Kazuhiko Ito , Akihiko Gemma , Masaru Nishitsuji , Masao Harada , Hiroshi Isobe , Ichiro Kinoshita , Satoshi Morita , Kunihiko Kobayashi , Koichi Hagiwara , Minoru Kurihara , Toshihiro Nukiwa

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2014 ASCO Annual Meeting

Session Type

Poster Highlights Session

Session Title

Lung Cancer - Non-small Cell Metastatic

Track

Lung Cancer

Sub Track

Metastatic Non–Small Cell Lung Cancer

Clinical Trial Registration Number

UMIN000002789

Citation

J Clin Oncol 32:5s, 2014 (suppl; abstr 8016)

DOI

10.1200/jco.2014.32.15_suppl.8016

Abstract #

8016

Poster Bd #

30

Abstract Disclosures

Similar Posters

First Author: Eisaku Miyauchi

First Author: Satoshi Oizumi

First Author: Si-Yu Wang

First Author: Wenfeng Fang